Dyskeratosis congenita (DC) is a rare-inherited bone marrow failure syndrome associated with multi-system disorder. To summarize the clinical features, epidemiology, and treatment of DC in mainland China, we retrospectively reviewed the medical records of two patients diagnosed with DC at our hospital and published reports on other DC patients in mainland China. The clinical features of 82 DC patients were summarized. The median age of onset was 5 years, but the median age at diagnosis was 16 years. Bone marrow failure occurred at a high rate of 44% and early, with a median onset age of 6 years (range 1–40 years). Only DKC1, TINF2, and TERT mutations were reported, which is a relatively simple signature. Aplastic anemia was treated mainly with low-dose androgens, glucocorticoids, or allogeneic hematopoietic stem cell transplantation, with an efficacy of 39% (14/36). In China, DC is relatively common in infants, with early age of onset but delayed diagnosis. Bone marrow failure occurred at a high rate and early. Improvement in the knowledge and awareness of DC combined with gene mutation tests will facilitate diagnosis and therapy in its early stages.
Dyskeratosis congenita Clinical feature China Aplastic anemia Bone marrow failure syndrome
This is a preview of subscription content, log in to check access.
This study was funded by Advanced Suitable Technology Popularization Project of Shanghai Health System (Grant number 2013SY073).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Alter BP, Giri N, Savage SA, Rosenberg PS. Cancer in dyskeratosis congenita. Blood. 2009;113:6549–57.CrossRefGoogle Scholar
Walne AJ, Dokal I. Advances in the understanding of dyskeratosis congenita. Br J Haematol. 2009;145:164–72.CrossRefGoogle Scholar
Nishio N, Kojima S. Recent progress in dyskeratosis congenita. Int J Hematol. 2010;92:419–24.CrossRefGoogle Scholar
Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172:187–207.CrossRefGoogle Scholar
Shimamura A, Alter BP. Pathophysiology and management of inherited bone marrow failure syndromes. Blood Rev. 2010;24:101–22.CrossRefGoogle Scholar
Knight S, Vulliamy T, Copplestone A, Gluckman E, Mason P, Dokal I. Dyskeratosis Congenita (DC) Registry: identification of new features of DC. Br J Haematol. 2015;103:990–6.CrossRefGoogle Scholar
Doka I. Dyskeratosis congenita. Hematology Am Soc Hematol Educ Program. 2011; 2011:480–6.CrossRefGoogle Scholar
Ballew BJ, Savage SA. Updates on the biology and management of dyskeratosis congenita and related telomere biology disorders. Expert Rev Hematol. 2013;6(3):327–37.CrossRefGoogle Scholar
Zhang JY, An WB, Zhang L, Chang LX, Qi BQ, Liu TF, et al. Genotype analysis and telomere length measure in patients with dyskeratosis congenita. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015;23:212–6.Google Scholar
Liu X, Li XY, Deng WP, Dong X, Zhang QLX, Hu ZZ. Telomere length in patients with dyskeratosis congenita in a Chinese Family. Int J Genet. 2012;35:157–60.Google Scholar
Zhou A, Xia XX, Chen Z, Li FZL, Liang XS. Bone marrow transplantation in the treatment of two cases of dyskeratosis congenita. Zhonghua Xue Ye Xue Za Zhi. 2001;22:407.Google Scholar
Buchbinder D, Nugent DJ, Fillipovich AH. Wiskott–Aldrich syndrome: diagnosis, current management, and emerging treatments. Appl Clin Genet. 2014;7:55–66.CrossRefGoogle Scholar
Fernández García MS, Teruya-Feldstein J. The diagnosis and treatment of dyskeratosis congenita: a review. J Blood Med. 2014; 2014(default):157–67.Google Scholar
Elmahadi S, Muramatsu H, Kojima S. Allogeneic hematopoietic stem cell transplantation for dyskeratosis congenita. Curr Opin Hematol. 2016;23:501–7.CrossRefGoogle Scholar
Khincha PP, Wentzensen IM, Giri N, Alter BP, Savage SA. Response to androgen therapy in patients with dyskeratosis congenita. Br J Haematol. 2014;165:349–57.CrossRefGoogle Scholar
Agarwal S. Evaluation and management of hematopoietic failure in dyskeratosis congenita. Hematol Oncol Clin N Am. 2018;32:669–85.CrossRefGoogle Scholar
Kirwan M, Beswick R, Yulliamy T, Nathwani AC, Walne AJ, Casimir C. Exogenous TERC alone can enhance proliferative potential, telomerase activity and telomere length in lymphocytes from dyskeratosis congenita patients. Br J Haematol. 2009;144:771–81.CrossRefGoogle Scholar
Kirwan M, Doka I. Dyskeratosis congenita, stem cell and telomeres. Biochim Biophys Acta. 2009;1792:371–9.CrossRefGoogle Scholar
Savage SA, Bertuch AA. The genetics and clinical manifestations of telomere, biology disorders. Genet Med. 2010;12:753–64.CrossRefGoogle Scholar
Mason PJ, Bessler M. The genetics of dyskeratosis congenita. Cancer Genet. 2011;204:635–45.CrossRefGoogle Scholar
Yamaguchi H, Sakaguchi H, Yoshida K, Yabe M, Yabe H, Okuno Y, et al. Clinical and genetic features of dyskeratosis congenita, cryptic dyskeratosis congenita, and Hoyeraal-Hreidarsson syndrome in Japan. Int J Hematol. 2015;102:544–52.CrossRefGoogle Scholar
Xu J, Khincha PP, Giri N, Alter BP, Savage SA, Wong JM. Investigation of chromosome X inactivation and clinical phenotypes in female carriers of DKC1 mutations. Am J Hematol. 2016;91:1215–20.CrossRefGoogle Scholar